11 results on '"Hallett SR"'
Search Results
2. A numerical study of the effect of draping on the mechanical properties of 3d woven composites
- Author
-
International Conference on Composite Materials (22nd : 2019 : Melboune, VIC.), Topalidis, I, El Said, B, Thompson, AJ, Keulen, J, and Hallett, SR
- Published
- 2019
3. Liquid processable, thermally stable, hydrophobic, phenolic-triazine resins for advanced composite applications
- Author
-
International Conference on Composite Materials (22nd : 2019 : Melboune, VIC.), Tsiamis, A, Iredale, RJ, Backhouse, R, Hallett, SR, and Hamerton, I
- Published
- 2019
4. An experimental investigation of the consolidation behaviour of uncured prepregs under processing conditions
- Author
-
Nixon-Pearson, OJ, primary, Belnoue, JP-H, additional, Ivanov, DS, additional, Potter, KD, additional, and Hallett, SR, additional
- Published
- 2016
- Full Text
- View/download PDF
5. Finite modelling of tow geometry in 3D woven fabrics
- Author
-
Mahadik, Y and Hallett, SR
- Abstract
A finite element model of a 3D woven angle interlock fabric undergoing compaction based on the multi-element digital chain technique has been developed. The aim was to create a kinematic model to predict the internal architectural features in a commercial off-the-shelf code. A statistical analysis of yarn crimp and resin channel size was carried out on sections from the model at increasing levels of compaction and compared to laboratory-manufactured samples with the same weave style. Results show a good correlation between overall mean crimp values in the warp, weft and weaver yarns as well as reasonable accuracy in the frequency distribution of local crimp angles. The trend in resin channel size with respect to increasing levels of compaction was also good but significant discrepancies in the absolute dimensions of a resin channel were present due to limitations in controlling the yarn bundle internal interactions in the model. A finite element model of a 3D woven angle interlock fabric undergoing compaction based on the multi-element digital chain technique has been developed. The aim was to create a kinematic model to predict the internal architectural features in a commercial off-the-shelf code. A statistical analysis of yarn crimp and resin channel size was carried out on sections from the model at increasing levels of compaction and compared to laboratory-manufactured samples with the same weave style. Results show a good correlation between overall mean crimp values in the warp, weft and weaver yarns as well as reasonable accuracy in the frequency distribution of local crimp angles. The trend in resin channel size with respect to increasing levels of compaction was also good but significant discrepancies in the absolute dimensions of a resin channel were present due to limitations in controlling the yarn bundle internal interactions in the model.
- Published
- 2010
6. The RNA binding proteins LARP4A and LARP4B promote sarcoma and carcinoma growth and metastasis.
- Author
-
Coleman JC, Tattersall L, Yianni V, Knight L, Yu H, Hallett SR, Johnson P, Caetano AJ, Cosstick C, Ridley AJ, Gartland A, Conte MR, and Grigoriadis AE
- Abstract
RNA-binding proteins (RBPs) are emerging as important regulators of cancer pathogenesis. We reveal that the RBPs LARP4A and LARP4B are differentially overexpressed in osteosarcoma and osteosarcoma lung metastases, as well as in prostate cancer. Depletion of LARP4A and LARP4B reduced tumor growth and metastatic spread in xenografts, as well as inhibiting cell proliferation, motility, and migration. Transcriptomic profiling and high-content multiparametric analyses unveiled a central role for LARP4B, but not LARP4A, in regulating cell cycle progression in osteosarcoma and prostate cancer cells, potentially through modulating key cell cycle proteins such as Cyclins B1 and E2, Aurora B, and E2F1. This first systematic comparison between LARP4A and LARP4B assigns new pro-tumorigenic functions to LARP4A and LARP4B in bone and prostate cancer, highlighting their similarities while also indicating distinct functional differences. Uncovering clear biological roles for these paralogous proteins provides new avenues for identifying tissue-specific targets and potential druggable intervention., Competing Interests: The authors declare that they have no competing interests., (© 2024.)
- Published
- 2024
- Full Text
- View/download PDF
7. LARP4A and LARP4B in cancer: The new kids on the block.
- Author
-
Coleman JC, Hallett SR, Grigoriadis AE, and Conte MR
- Subjects
- Humans, Autoantigens genetics, RNA-Binding Proteins genetics, Genes, Tumor Suppressor, Ribonucleoproteins genetics, Ribonucleoproteins metabolism, Neoplasms genetics
- Abstract
Recent developments have mounted a stunning body of evidence underlying the importance of RNA binding proteins (RBPs) in cancer research. In this minireview we focus on LARP4A and LARP4B, two paralogs belonging to the superfamily of La-related proteins, and provide a critical overview of current research, including their roles in cancer pathogenesis and cell proliferation, migration, cell cycle and apoptosis. We highlight current controversies surrounding LARP4A and LARP4B and conclude that their complex roles in tumorigenesis are cell-, tissue- and context-dependent, warning that caution must be exercised before categorising either protein as an oncoprotein or tumour-suppressor. We also reveal that LARP4A and LARP4B have often been confused with one another, adding uncertainty in delineating their functions. We suggest that further functional and mechanistic studies of LARP4 proteins present significant challenges for future investigations to recognise the vital contributions of these RBPs in cancer research., Competing Interests: Declaration of Competing Interest The authors declare there are no conflicts of interest to disclose., (Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
8. ChAdOx1 nCoV-19 vaccine elicits monoclonal antibodies with cross-neutralizing activity against SARS-CoV-2 viral variants.
- Author
-
Seow J, Graham C, Hallett SR, Lechmere T, Maguire TJA, Huettner I, Cox D, Khan H, Pickering S, Roberts R, Waters A, Ward CC, Mant C, Pitcher MJ, Spencer J, Fox J, Malim MH, and Doores KJ
- Subjects
- Antibodies, Monoclonal, Antibodies, Neutralizing, Antibodies, Viral, COVID-19 Vaccines, ChAdOx1 nCoV-19, Humans, Vaccination, COVID-19 prevention & control, SARS-CoV-2
- Abstract
Although the antibody response to COVID-19 vaccination has been studied extensively at the polyclonal level using immune sera, little has been reported on the antibody response at the monoclonal level. Here, we isolate a panel of 44 anti-SARS-CoV-2 monoclonal antibodies (mAbs) from an individual who received two doses of the ChAdOx1 nCoV-19 (AZD1222) vaccine at a 12-week interval. We show that, despite a relatively low serum neutralization titer, Spike-reactive IgG+ B cells are still detectable 9 months post-boost. Furthermore, mAbs with potent neutralizing activity against the current SARS-CoV-2 variants of concern (Alpha, Gamma, Beta, Delta, and Omicron) are present. The vaccine-elicited neutralizing mAbs form eight distinct competition groups and bind epitopes overlapping with neutralizing mAbs elicited following SARS-CoV-2 infection. AZD1222-elicited mAbs are more mutated than mAbs isolated from convalescent donors 1-2 months post-infection. These findings provide molecular insights into the AZD1222 vaccine-elicited antibody response., Competing Interests: Declaration of interests The authors declare no competing interests., (Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
9. Neutralizing antibody activity in convalescent sera from infection in humans with SARS-CoV-2 and variants of concern.
- Author
-
Dupont L, Snell LB, Graham C, Seow J, Merrick B, Lechmere T, Maguire TJA, Hallett SR, Pickering S, Charalampous T, Alcolea-Medina A, Huettner I, Jimenez-Guardeño JM, Acors S, Almeida N, Cox D, Dickenson RE, Galao RP, Kouphou N, Lista MJ, Ortega-Prieto AM, Wilson H, Winstone H, Fairhead C, Su JZ, Nebbia G, Batra R, Neil S, Shankar-Hari M, Edgeworth JD, Malim MH, and Doores KJ
- Subjects
- Adult, Aged, Aged, 80 and over, Antibodies, Viral immunology, COVID-19 therapy, COVID-19 virology, COVID-19 Vaccines, Female, Humans, Immunization, Passive, Immunoglobulin G, Immunoglobulin M, Male, Middle Aged, Mutation, Neutralization Tests, SARS-CoV-2 genetics, Spike Glycoprotein, Coronavirus genetics, Vaccination, Young Adult, COVID-19 Serotherapy, Antibodies, Neutralizing blood, Antibodies, Neutralizing immunology, Antibodies, Viral blood, COVID-19 immunology, SARS-CoV-2 immunology
- Abstract
COVID-19 vaccine design and vaccination rollout need to take into account a detailed understanding of antibody durability and cross-neutralizing potential against SARS-CoV-2 and emerging variants of concern (VOCs). Analyses of convalescent sera provide unique insights into antibody longevity and cross-neutralizing activity induced by variant spike proteins, which are putative vaccine candidates. Using sera from 38 individuals infected in wave 1, we show that cross-neutralizing activity can be detected up to 305 days pos onset of symptoms, although sera were less potent against B.1.1.7 (Alpha) and B1.351 (Beta). Over time, despite a reduction in overall neutralization activity, differences in sera neutralization potency against SARS-CoV-2 and the Alpha and Beta variants decreased, which suggests that continued antibody maturation improves tolerance to spike mutations. We also compared the cross-neutralizing activity of wave 1 sera with sera from individuals infected with the Alpha, the Beta or the B.1.617.2 (Delta) variants up to 79 days post onset of symptoms. While these sera neutralize the infecting VOC and parental virus to similar levels, cross-neutralization of different SARS-CoV-2 VOC lineages is reduced. These findings will inform the optimization of vaccines to protect against SARS-CoV-2 variants., (© 2021. The Author(s).)
- Published
- 2021
- Full Text
- View/download PDF
10. Antibody longevity and cross-neutralizing activity following SARS-CoV-2 wave 1 and B.1.1.7 infections.
- Author
-
Dupont L, Snell LB, Graham C, Seow J, Merrick B, Lechmere T, Hallett SR, Charalampous T, Alcolea-Medina A, Huettner I, Maguire TJA, Acors S, Almeida N, Cox D, Dickenson RE, Galao RP, Jimenez-Guardeño JM, Kouphou N, Lista MJ, Pickering S, Ortega-Prieto AM, Wilson H, Winstone H, Fairhead C, Su J, Nebbia G, Batra R, Neil S, Shankar-Hari M, Edgeworth JD, Malim MH, and Doores KJ
- Abstract
As SARS-CoV-2 variants continue to emerge globally, a major challenge for COVID-19 vaccination is the generation of a durable antibody response with cross-neutralizing activity against both current and newly emerging viral variants. Cross-neutralizing activity against major variants of concern (B.1.1.7, P.1 and B.1.351) has been observed following vaccination, albeit at a reduced potency, but whether vaccines based on the Spike glycoprotein of these viral variants will produce a superior cross-neutralizing antibody response has not been fully investigated. Here, we used sera from individuals infected in wave 1 in the UK to study the long-term cross-neutralization up to 10 months post onset of symptoms (POS), as well as sera from individuals infected with the B.1.1.7 variant to compare cross-neutralizing activity profiles. We show that neutralizing antibodies with cross-neutralizing activity can be detected from wave 1 up to 10 months POS. Although neutralization of B.1.1.7 and B.1.351 is lower, the difference in neutralization potency decreases at later timepoints suggesting continued antibody maturation and improved tolerance to Spike mutations. Interestingly, we found that B.1.1.7 infection also generates a cross-neutralizing antibody response, which, although still less potent against B.1.351, can neutralize parental wave 1 virus to a similar degree as B.1.1.7. These findings have implications for the optimization of vaccines that protect against newly emerging viral variants.
- Published
- 2021
- Full Text
- View/download PDF
11. Use of microfasteners to produce damage tolerant composite structures.
- Author
-
Partridge IK and Hallett SR
- Abstract
The paper concerns the mechanical performance of continuous fibre/thermosetting polymer matrix composites reinforced in the through-thickness direction with fibrous or metallic rods or threads in order to mitigate against low delamination resistance. Specific illustrations of the effects of microfasteners in reducing delamination crack growth are made for Z-pinned and tufted composites. Response to loading in such 'structured materials' is subject to multiple parameters defining their in-plane and out-of-plane properties. Single microfastener mechanical tests are well suited to establish the crack bridging laws under a range of loading modes, from simple delamination crack opening to shear, and provide the basis for predicting the corresponding response of microfastener arrays, within a given material environment. The fundamental experiments on microfasteners can be used to derive analytical expressions to describe the crack bridging behaviour in a general sense, to cover all possible loadings. These expressions can be built into cohesive element constitutive laws in a finite-element framework for modelling the effects of microfastener arrays on the out-of-plane mechanical response of reinforced structural elements, including the effects of known manufacturing imperfections. Such predictive behaviour can then be used to assess structural integrity under complex loading, as part of the component design process. This article is part of the themed issue 'Multiscale modelling of the structural integrity of composite materials'., (© 2016 The Authors.)
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.